HC Wainwright & Co. Initiates Coverage On Connect Biopharma Hldgs with Buy Rating, Announces Price Target of $7
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy rating and a price target of $7.

March 04, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Connect Biopharma Hldgs receives a Buy rating from HC Wainwright & Co. with a price target of $7.
The initiation of coverage by a reputable analyst firm like HC Wainwright & Co. with a Buy rating and a specific price target can significantly influence investor perception and confidence in Connect Biopharma Hldgs. This positive outlook is likely to attract attention to CNTB, potentially driving up its stock price in the short term as investors react to the analyst's recommendation.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100